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Poster Session-I 85patients with SD achieved a 40% (0–80) OR rate (p 5 .02) for
a 50% (19–80) OS probability at 2 years (p 5 .001). Of the 4 pa-
tients in response at time of transplant, 3 increased their response
(PR 5 2; CR 5 1) and 3 were alive after 2 years. This study shows
that RIC-ASCT can be safely performed in BrC pts without
high transplant related mortality. However we show evidences
that pts with highly progressive disease do not benefit from this ap-
proach. In contrast, a high rate of response associated with pro-
longed survival can be achieved in patients with slowly
progressive disease. Better results could perhaps be achieved only
in pts in the initial disease phase when treatment disease resistance
has not occurred.233
INCREASED FREQUENCY AND RESPONSIVENESS OF PSA-SPECIFIC T
CELLS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR PROS-
TATE CANCER
Mattsson, J., Okas, M., Ringden, O., Uhlin, M. Clinical Immunology,
Stockholm, Sweden
Therapies for localized prostate cancer include curative surgery
and radiotherapy while treatment of metastatic disease is often in-
sufficient. Therefore, we started to investigate the potential of allo-
geneic SCT as a treatment for non-curable prostate cancer. A
patient underwent allogeneic SCT from his HLA-identical sister
after a non-myeloablative conditioning regimen as treatment for
his metastatic prostate adenocarcinoma. The patient was treated
with donor lymphocyte infusions after SCT due to threatening re-
jection. Frequencies of prostate-specific T cells in the peripheral
blood of the patient, sibling donor and a group of control individ-
uals were determined by flow cytometry using tetrameric and pen-
tameric HLA A2 complexes containing peptides derived from the
prostate specific antigen (PSA). Cytotoxic activity of PSA-
peptide-specific T-cells against peptide-pulsed target cells was
analyzed ex vivo by 51Cr-release assays. Stable clinical and labora-
tory remission lasting for more than 5 years was observed after
SCT. Using HLA containing pentamers with PSA-derived pep-
tides we could detect prostate-specific CD81 T cells in this patient
in high frequencies over several months. Furthermore, higher fre-
quencies of PSA-specific T-cells were revealed in the peripheral
blood of the patient and female controls as compared with male
healthy controls. Recently the PSA levels in the patient started to
increase and prostate biopsies showed prostate carcinoma in 3/8 bi-
opsies, Gleason 414, totally 3.5 mm of cancer (of 100 mm totally).
Due to this progression we have initiated a protocol for adoptive
transfer of allogeneic PSA-specific T cells from the patient. We
will, by using pentamers and flourocrome specific beads separate
out PSA specific T cells from the patient. In order to break a possi-
ble tolerance we will keep them in high concentration of IL-2
and the respective peptides in vitro culture over night before injec-
tion back into the patient. Clinical data of this novel therapy will
be presented at the meeting.Our data suggest that allogeneic
SCT led to the generation of a T cell mediated prostate-specific
immunity in the reported patient. The in vitro and ex vivo immuno-
logical monitoring performed indicate an adjuvant anti-tumor
effect of PSA-specific T cells. This report presents a novel
treatment approach involving allogeneic SCT in prostate cancer
patients who do not respond to chemotherapy and/or cannot
undergo prostectomy.STEM CELL BIOLOGY
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COMPLETE LONG-TERM HEMATOPOIETIC ENGRAFTMENT BY LINEAGE-
DEPLETED ALDH CD341 UCB CELLS
Liu, C.1, DeOliveira, D.1, Sempowski, G.D.2, Chao, N.J.1, Chen, B.J.1,
Storms, R.W.1 1Duke University Medical Center, Durham, NC;
2Duke University Medical Center, Durham, NC
In previous work, we fractionated CD341 umbilical cord blood
(UCB) progenitors to purify cells that express high levels of aldehydedehydrogenase (ALDH). The ALDHbr CD341 cells were enriched
with progenitors that engraft NOD/SCID mice in both short-term
(6–8 week) and long-term (.18 week) transplants. In contrast,
ALDHneg CD341 progenitors were not a significant source of
NOD/SCID repopulating cells. These data strongly imply that
transplantable human progenitors express ALDH; however, one
shortcoming for that work remains that human hematopoietic devel-
opment in NOD/SCID mice is limited to the myeloid and B-lym-
phoid lineages. Because the pace of T cell engraftment is a critical
clinical concern, we have adopted the use of the NOD/SCID-
IL2Rgnull mouse xenograft transplant model. In the current study,
20 mice were transplanted with lineage-depleted ALDHbr CD341
progenitors at doses that ranged from 3,000 to 30,000 cells. In con-
trol studies, similar doses of ALDHneg CD341 cells did not provide
long-term engraftment. So that we might characterize the behavior
of individual UCB, each transplant graft was derived from a single
UCB. In addition, each UCB was assayed in multiple different
mice. Twelve of 13 mice that survived until 21 weeks post-transplant
demonstrated multiple-lineage human hematopoietic engraftment.
Human T, B, NK and myeloid cells were detected in the bone mar-
row and spleen. In addition, in 9 mice human T cells were detected in
the thymus. Furthermore, 7 mice had sufficient thymus tissue to
measure T cell Receptor Excision Circles (TREC). By that assay, 3
of those mice demonstrated active human T cell rearrangements.
As anticipated, the level of engraftment to all tissues was cell
dose-dependent. One strength for this xenograft model was that
engraftment could be monitored over time within the peripheral
blood. Human B cells engrafted within 7 weeks post-transplant
and were detected in 17 of 19 mice ($ 5 B cells/mL). At 16 weeks
post-transplant, 15 of 18 mice maintained detectable B cells. In
contrast, human T cells emerged later, beginning at 13 weeks
post-transplant. However, even by 16 weeks post-transplant, T cells
were only detectable in the peripheral blood of 6 of 18 mice ($ 5 T
cells/mL). These studies provided evidence that ALDHbr CD341
cells establish both short- and long-term hematopoiesis in NOD/
SCID-IL2Rgnull mice. The emergence of T cells was the most
stringent test for long-term engraftment.235
HUMAN EMBRYONIC STEM CELLS-DERIVED HEMANGIOBLAST EXPRESS
HLA-ANTIGENS
Basak, G.W.1, Yasukawa, S.2, Alfaro, A.2, Miniev, B.2, Carrier, E.2
1Medical University of Warsaw, Warsaw, Poland; 2University of
California San Diego, La Jolla, CA
The initial differentiation of vascular endothelium and hemato-
poietic cells during embryogenesis occurs in the mesodermal layer
of the yolk sac, yielding structures called blood islands. We hypoth-
esized that under specific conditions this process can be recapitulated
in embryoid body (EB)-derived cell cultures and that such cells will
be able to form colonies of functional cells with dual hematopoietic/
endothelial potential. We used two-step differentiation technology
to obtain the bipotential blast cells from human embryonic stem cells
(hES). This involved short differentiation in our EB system followed
by differentiation in semisolid culture media supplemented with
mixture of cytokines. We have shown that the occurrence of heman-
gioblast (blast colony-forming cells) – BL-CFC during EB differen-
tiation (day 0–6) is transient and peaks on day 3. The emergence of
this event was associated with expression of T (early mesoderm
gene), and was suppressed by the development of endoderm layer.
Similarly, the highest BL-CFC count was associated with dramatic
increase in early hematopoietic/endothelial genes: CD34, CD31
and KDR. The similar pattern of expression of Patch1 and Gli1
genes suggested association with hedgehog (Hh) pathway. BL-
CFC colonies were composed of 30–50 blast cells on day 6. These
cells had homogenous morphology in Wright-Giemsa stain with
a big nucleus containing disorganized chromatin and a narrow rim
of cytoplasm filled with large-size granules. As shown by FACS stain-
ing, they were heterogenous and expressed markers of early hemato-
poietic and endothelial cells (CD31, CD34, VE-cadherin, Flt-1) and
mature differentiated cells (CD45, CD33, CD146). Some of them
expressed fetal and embryonic globin genes as shown RT-PCR.
Moreover, they could be characterized by higher expression of
HLA class I molecules when compared to hES and EB cells.
86 Poster Session-IWhen in endothelial cell culture conditions, the blast cells differen-
tiated to endothelial cells which had the ability to take up Dil-
Ac-LDL and formed complex vascular networks in Matrigel.
We concluded that: 1) hemangioblast exist transiently in early
embryonic development and can form single cell-derived colonies;
2) differentiation of hemangioblasts can be tracked by the use of
chosen molecular markers; 3) blast colonies consist of cells having
properties of endothelial or hematopoietic precursors, 4) blast cells
can be potentially used in regenerative medicine due to their low
immunostimulatory potential.
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NASAL EPITHELIAL CELLS OF DONOR ORIGIN AFTER ALLOGENEIC HCT:
RESULT OF STEM-CELL PLASTICITY, CELL-FUSION OR TRANSFER OF
EPITHELIAL CELL PRECURSORS WITH THE GRAFT?
Khan, F., Sy, S., Louie, P., Smith, M., Chernos, J., Lee, R., Berka, N.,
Sinclair, G., Leigh, R., Proud, D., Russell, J., Storek, J. University of Cal-
gary, Calgary, AB, Canada
Background: Epithelial cells (ECs) are generally believed to orig-
inate from epithelial stem cells and not from hematopoietic stem
cells (HSCs). However, detection of donor-type myocytes, neurons
and skin, liver, lung or intestinal epithelial cells after allogeneic
HCT (using XY-FISH and sex-mismatched donor-recipient pairs)
has suggested that HSCs may carry a degree of developmental
plasticity. This is controversial given artifacts of the XY-FISH or
the possibility of hematopoietic-EC cell fusion. Alternatively,
donor-type ECs post-transplant could originate from ECs or their
precursors transferred with the graft. The goal of this study was to
determine whether donor origin nasal ECs exist in HCT recipients,
and if so, then the underlying mechanism.
Methods: We collected nasal scrapings and whole blood from 35
HCT survivors, either early (2–3 months, n5 15) or late (4–22 years,
n5 20) post-transplant. Bone marrow was grafted in 15 of the 20 late
post-transplant patients whereas filgrastim-mobilized blood stem
cells were grafted in all 15 early and 5 late post-transplant patients.
To avoid the limitations of XY-FISH, chimerism of the ECs was de-
termined as: Nasal cells were stained with cytokeratin (CK) and
CD45 antibodies. True ECs (CK1CD45_) were laser captured.
DNA extracted from the captured ECs and blood leukocytes was
PCR amplified for a panel of 15 autosomal STR markers and an
XY-differentiating locus (ABI-Identifiler). In addition, a combina-
tion of immunofluorescence staining for CK and FISH for two auto-
somes was used in 10 patients to assess cell fusion. Epithelial cell
precursors in 8 graft specimens were searched by using magnetic sep-
aration with CD36 microbeads and staining with CK.
Results: In all 35 HCT survivors, ECs of donor origin were iden-
tified accounting for 2.2% to 12.3% (median 6.2 %) of the nasal ECs.
The percentage appeared to be2-fold higher late posttransplant in
marrow compared to blood stem cell recipients and was similar in
blood stem cell recipients early and late posttransplant. None of
the nasal ECs in 10 HCT survivors exhibited the presence of cell fu-
sion. Epithelial cells/epithelial cell precursors (CD361CK1) were
found in each of the 8 graft specimens.
Conclusion: Donor origin nasal ECs were identified even with
a method that obviates the artifacts of XY-FISH. The underlying
mechanism appears to be trans-differentiation of HSCs into ECs
or the transfer of ECs (or their precursors) with the graft, but not
cell fusion.237
ISOLATION AND EXPANSION OF OLIGODENDROCYTES FROM THAWED,
CRYOPRESERVED HUMAN UMBLILICAL CORD BLOOD
Tracy, E.1, Gentry, T.2, Shoulars, K.1, Hughes, M.3, Kurtzberg, J.1
1Duke University, Durham, NC; 2Aldagen, Durham, NC; 3Columbia
University, NY, NY
While transplantation of unrelated umbilical cord blood (UCB)
halts the progression of neurological damage in children with lyso-
somal storage diseases (LSD), it does not necessarily reverse the
damage sustained before transplant. Isolation and expansion of cen-
tral nervous system progenitor cells from UCB has potential thera-
peutic application in treating these patients. We recently described
the reliable isolation and expansion of oligodendrocyte-like precur-
sor cells (OPC) from freshly collected, non-crypreserved UCB(Tracy et al. Cytotherapy. 2008, 3:1–8). We anticipate utilizing these
cells as adjuvant, targeted therapy to reduce the time to donor cell
correction/prevention of disease-induced CNS injury. This ap-
proach will require use of cyropreserved donor UCB. We now dem-
onstrate the feasibility of isolating and expanding OPCs from a series
of thawed, cryopreserved UCB units. Cryopreserved UCB units
were thawed using a standard protocol employed in clinical trans-
plantation. Mononuclear cells were isolated by either ficoll density
separation or centrifugation after a dextran-albumin wash. Fresh
UCB units underwent hetastarch depletion of red blood cells then
mononuclear cell isolation by ficoll density gradient separation.
Cells were plated at 3  10(6) cells/ml in media containing platelet
derived growth factor, neurotopin 3, vascular endothelial growth
factor, and triiodothyronine. All UCB unit cultures were trypsinized
at 21 days, counted, then characterized by flow cytometry after being
fixed, permeablized, and labeled with the following antibodies: anti-
oligidendrocyte marker 4 (O4), anti-oligidendrocyte marker 1 (O1),
anti-myelin basic protein (MBP). To examine phenotypic changes
over time, cultures from two units (one thawed, one fresh) were an-
alyzed weekly over 4 weeks. On flow cytometric analysis, 78% of
thawed UCB units yielded O4-expressing cells as at least 20% of to-
tal events compared with 95% of fresh UCB units.
Table 1: Characteristics of UCB-Derived Oligodendrocytes
Thawed UCB Units Fresh UCB UnitsTotal Units Cultured 27 19
Mean # mononuclear
cells plated/UCB Unit
3.03  10 (8) 1.53  10 (8)Final oligodendrocyte
cell count/UCB Unit8.41  10 (5) 3.41  10 (6)Units with O4 expression
.20% of total events21 (78%) 18 (95%)Events in gate as % total events 54.06 76.54
O4 expression (% of gated)
85.93 87.88
85.93 87.88O1 expression (% of gated) 89.84 88.40
MBP expression (% of gated) 28.87 30.51
Co-expression of MBP-O1
(% of gated)
26.67 30.50Average OPC yield per UCB unit was less for thawed units (8.41
10(5)) than fresh (3.41 10(6)). However, expression of O1, O4, and
MBP was similar. We also noted early expression of the preoligoden-
drocyte marker O4 by 1–2 weeks in culture, followed by expression
of mature oligodendrocyte markers O1 and MBP over 2–4 weeks.
Our results demonstrate that oligodendrocyte precursor cells can
be derived reliably from thawed, cryopreserved UCB units, and
suggest the feasibility of using these cells in human clinical trials.238
ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) FOR RELAP-
SED, REFRACTORY MYELOID LEUKEMIA AND MDS USING CLOFARABINE
(CLO)6 FLUDARABINE (FLU) WITH IV BUSULFAN (BU) AS CONDITION-
ING THERAPY
Andersson, B.S.1, de Lima, M.1, Popat, U.1, Jones, R.B.1, Shpall, E.J.1,
Hosing, C.1, McAdams, P.L.1, Alousi, A.M.1, Kebriaei, P.1,
Champlin, R.E.1, Worth, L.L.3, Madden, T.L.3, Kazerooni, R.4 1UT
M.D. Anderson Cancer Center, Houston, TX;2,3,4
IV Bu/Flu is a safe conditioning regimen, but relapses still occur.
We decided to replace Flu with Clo to enhance the regimen antileu-
kemic effect. The immunosuppressive capacity of Clo is unknown,
and we gradually replaced Flu with Clo, aimed at retaining safety
while evaluating the engraftment-promoting capacity of Clo.
Methods: Patients were randomized to: Arm I: Clo:Flu 10:30 mg/
m2, Arm II 20:20 mg/m2, Arm III 30:10 mg/m2; Arm IV Clo 40 mg/
m2. The nucleoside analog(s) were/was infused over 1 hour daily4
days; Bu was infused over 3 hours (daily AUC of 6,000 mcMol-min6
10%), immediately after the nucleoside analog(s). 25 pts have been
enrolled, 22 are evaluable for engraftment and survival beyond day
100; 16 were males; median age was 46 yrs (6–59). 7 pts had CML
(BC: 1, first AP: 3, second AP: 2, and late first CP: 1). 18 patients
